This paper is only available as a PDF. To read, Please Download here.
Abstract
Hypertrichosis occurs as an undesirable adverse reaction in the majority of hypertensive
patients treated with minoxidil (Loniten tablets, Upjohn Company, Kalamazoo, MI).1–3 Nevertheless, its potential topical use for the treatment of alopecia4 has caused much publicity and interest in several topical formulations of minoxidil
recently available to selected patient populations. First, patients have participated
in sanctioned Investigational New Drug studies using unique investigational formulations
of The Upjohn Company. Secondly, patients have received Upjohn's topical 2% minoxidil
solution marketed in a country outside of the United States, such as Canada. Lastly,
patients have had a local pharmacist prepare an extemporaneous minoxidil solution
from Loniten tablets.5,6
The pharmacodynamics of such extemporaneous preparations are variable and may not
be directly comparable to Upjohn's unique marketed product. Consequently in 1985,
the Food and Drug Administration (FDA) issued an order to halt the use of Loniten
Tablets for preparing extemporaneous topical minoxidil solutions for alopecia5; however, such nonapproved usage constituted by far the major route of exposure to
topical minoxidil.7
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinics in DermatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Hypertrichosis due to minoxidil.Br J dermatol. 1979; 101: 593-595
- Reversal of baldness in a patient receiving minoxidil for hypertension.N Engl J Med. 1980; 303: 1480-1481
- Reversal of male pattern baldness by minoxidil.Cutis. 1981; 28: 551-553
- Topical minoxidil therapy and hair regrowth.Arch dermatol. 1985; 121: 191-192
- FDA Drug Bull. 1985; 15: 38
- J Am Acad dermatol. 1986; 14: 828-829
- Topical minoxidil.Arch dermatol. 1987; 123: 62-65
- Topical minoxidil useful in 18% of patients with androgenetic alopecia: a study of 430 cases.Dermatologica. 1986; 173: 136-138
- Minoxidil shows promise as hair growth agent in alopecia.Dermatology Times. April 1987; 8: 27
- Topically applied minoxidil in baldness.Int J dermatol. 1985; 24: 82-87
- Topical minoxidil for hair regrowth.J Am Acad dermatol. 1984; 11: 416-421
- Histological findings in androgenetic alopecia treated with topical minoxidil.Br J dermatol. 1982; 107: 20-21
The Upjohn Company. Data on file.
- Topical minoxidil therapy in hereditary androgenetic alopecia.Arch dermatol. 1985; 121: 197-202
- Topical minoxidil in early male pattern baldness.J Am Acad dermatol. 1985; 13: 185-192
- Topical minoxidil for male pattern baldness.Am J Med Sci. 1986; 291: 328-333
- Patterned loss of hair in man: types and incidence.Ann NY Acad Sci. 1951; 53: 708-728
- Dose-response study of topical minoxidil in male pattern baldness.J Am Acad dermatol. 1986; 15: 30-37
- The pathologic effect of minoxidil in male pattern alopecia.J Invest dermatol. 1986; 86: 459
Article info
Identification
Copyright
© 1988 Published by Elsevier Inc.
